Biliopancreatic limb length impacts metabolic dysfunction-associated steatotic liver disease trajectories after Roux-en-Y gastric bypass
In brief
Extending the biliopancreatic limb to at least 100 cm lowers liver disease scores by about one
In a retrospective cohort, patients receiving a long (at least 100 cm) biliopancreatic limb during Roux-en-Y gastric bypass showed significantly lower non-invasive steatohepatitis scores at 3 months (≈-1.2) and sustained reductions through two years, alongside better glycemic control and unchanged weight loss. The findings suggest limb length may enhance MASLD improvement without added nutritional risk, but prospective trials are needed.
- Journal
- Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery (Q1)
- Published
- 29 July 2026
- Study design
- Retrospective cohort
- Evidence level
- Level 3, Low (CEBM 3b)
- Authors
- Christopher Tuffs, Nadher Al Saleh, Annette Hauenschild, Lisa Sauerbier, Daniar Amin, Alen Kosovic, et al.
- PMID
- 42705981
- DOI
- 10.1016/j.soard.2026.07.016
Why clinicians should know about it
- Picked for Bariatric and Metabolic Surgery (paper of the day, 8 September 2026): Longer BPL improves MASLD after RYGB
Abstract
BACKGROUND: RYGB is an effective treatment option for metabolic dysfunction-associated steatotic liver disease (MASLD). The optimal configuration for the biliopancreatic limb (BPL) remains uncertain. OBJECTIVES: To assess whether BPL length in Roux-en-Y gastric bypass (RYGB) affects improvement in MASLD. SETTING: University Hospital Center. METHODS: We conducted a retrospective cohort study of adults who underwent RYGB between 2019 and 2024. Patients were dichotomized a priori by BPL length: ≈70 cm (short) versus ≥100 cm (long). Outcomes were evaluated at baseline, 3 months (3M), 1 year (1Y), and 2 years (2Y) postoperatively. Primary outcomes were MASLD-related noninvasive tests (NITs) including the Nonalcoholic Fatty Liver Disease (NAFLD) Fibrosis Score (NFS) and Noninvasive Nonalcoholic Steatohepatitis Detection Score (NI-NASH DS). RESULTS: Compared with short BPL, long BPL was associated with lower NI-NASH DS at 3M (-1.19; 95% confidence interval [CI], -1.93 to -.48; q < .01) and 1Y (-.77; 95% CI, -1.37 to -.15; q < .05) and lower NFS at 1Y (-.39; 95% CI, -.70 to -.09; q < .05) and 2Y (-.53; 95% CI, -.96 to -.10; q < .05). Glycated hemoglobin was lower at 1Y (-.10; 95% CI, -.20 to .00; q < .05) and 2Y (-.20; 95% CI, -.30 to -.00; q < .05), while total weight loss was similar. Total cholesterol and low-density lipoprotein cholesterol were lower at 1Y and 2Y. Nutritional markers were largely comparable. CONCLUSIONS: A longer BPL (≥100 cm) was associated with greater improvements in MASLD-related NIT trajectories at 1Y and 2Y after RYGB, with better glycemic control and similar weight loss, without evidence of nutritional deficiency.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.